[{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-23 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"NDI-5001","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NephroDI Therapeutics \/ McQuade Center","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI Therapeutics \/ McQuade Center"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Sound Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"NDI-5001","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NephroDI Therapeutics \/ Sound Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI Therapeutics \/ Sound Bioventures"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"RSVI-301","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RosVivo Therapeutics \/ Nexturn Bio","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Nexturn Bio"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"RSVI-301","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RosVivo Therapeutics \/ Nexturn Bio","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Nexturn Bio"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LXM.2","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Laxxon Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Inapplicable"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LXM.2","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Laxxon Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Inapplicable"},{"orgOrder":0,"company":"Civica Rx","sponsor":"GeneSys Biologics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Civica Rx \/ GeneSys Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Civica Rx \/ GeneSys Biologics"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Biosplice \/ Novo Nordisk"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"iTolerance","sponsor":"BIRD Foundation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ BIRD Foundation","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ BIRD Foundation"},{"orgOrder":0,"company":"iTolerance","sponsor":"Diabetes Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Diabetes Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Diabetes Research Institute"},{"orgOrder":0,"company":"iTolerance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Inapplicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"Neurodon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NDC-0009","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Neurodon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurodon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurodon \/ Inapplicable"},{"orgOrder":0,"company":"GentiBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"GentiBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GentiBio \/ Matrix Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"GentiBio \/ Matrix Capital Management"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repertoire Immune Medicines \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire Immune Medicines \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repertoire Immune Medicines \/ JDRF","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire Immune Medicines \/ JDRF"},{"orgOrder":0,"company":"Lygenesis","sponsor":"Imagine Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lygenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lygenesis \/ Imagine Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lygenesis \/ Imagine Pharma"},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Teplizumab","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune \/ JDRF"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RTX-T1D","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RTX-T1D","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune \/ JDRF"},{"orgOrder":0,"company":"W. L. Gore & Associates","sponsor":"ViaCyte Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Encapsulated Pancreatic Islet Precursor Cell","moa":"Insulin secretion","graph1":"Endocrinology","graph2":"Preclinical","graph3":"W. L. Gore & Associates","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"W. L. Gore & Associates \/ ViaCyte Inc","highestDevelopmentStatusID":"4","companyTruncated":"W. L. Gore & Associates \/ ViaCyte Inc"},{"orgOrder":0,"company":"Encellin","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"ENC-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Encellin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Encellin \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Encellin \/ Khosla Ventures"},{"orgOrder":0,"company":"Protomer Technologies","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Glucose Responsive Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Protomer Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protomer Technologies \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Protomer Technologies \/ Eli Lilly"},{"orgOrder":0,"company":"iTolerance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"iTOL-100","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iTolerance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Inapplicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"iTOL-101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iTolerance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Inapplicable"},{"orgOrder":0,"company":"Seraxis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"SR-01","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Seraxis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seraxis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Seraxis \/ Eli Lilly"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ABA-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"eGenesis","sponsor":"University of Miami","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"HuCo Islet Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eGenesis \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/ University of Miami"},{"orgOrder":0,"company":"Porosome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"T1D-PT101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Porosome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Porosome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Porosome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Sigilon Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SQZ TACs","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Sigilon Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Financing","leadProduct":"Insulin","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abvance Therapeutics \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"4","companyTruncated":"Abvance Therapeutics \/ Helmsley Charitable Trust"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Genprex","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Adimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adimune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adimune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adimune \/ Inapplicable"},{"orgOrder":0,"company":"Adimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adimune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adimune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adimune \/ Inapplicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"National Institute of Diabetes and Digestive Kidney Disease","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease","highestDevelopmentStatusID":"4","companyTruncated":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease"},{"orgOrder":0,"company":"Pluristyx","sponsor":"Humacyte","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"BioVascular Pancreas","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Pluristyx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluristyx \/ Humacyte","highestDevelopmentStatusID":"4","companyTruncated":"Pluristyx \/ Humacyte"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC451","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC451","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProLynx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ Inapplicable"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fractyl Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Endocrinology","graph2":"Preclinical","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Remedium Bio","sponsor":"National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RMD1202","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Remedium Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Remedium Bio \/ National Science Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Remedium Bio \/ National Science Foundation"},{"orgOrder":0,"company":"Anodyne Nanotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Anodyne Nanotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Anodyne Nanotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anodyne Nanotech \/ Inapplicable"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Ohio State University","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AgeX-BAT1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Ohio State University"},{"orgOrder":0,"company":"Junevity","sponsor":"Goldcrest Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Junevity","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Junevity \/ Goldcrest Capital","highestDevelopmentStatusID":"4","companyTruncated":"Junevity \/ Goldcrest Capital"},{"orgOrder":0,"company":"MRM Health","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"M008","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ International Flavors and Fragrances","highestDevelopmentStatusID":"4","companyTruncated":"MRM Health \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"GLP-1-Based Pancreatic Gene Therapy","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ BofA Securities","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ BofA Securities"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RJVA-001","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ Inapplicable"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"RSVI-301","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RosVivo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Brown Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosciences \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"XOMA","sponsor":"Amolyt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"AZP-40XX","moa":"PTH1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Amolyt Pharma","highestDevelopmentStatusID":"4","companyTruncated":"XOMA \/ Amolyt Pharma"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"University of Sheffield","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Delayed Clearance Parathyroid Hormone","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aeterna Zentaris \/ University of Sheffield","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Zentaris \/ University of Sheffield"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Teriparatide","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProLynx \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ National Institutes of Health"},{"orgOrder":0,"company":"Septerna","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Septerna \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Septerna \/ RA Capital Management"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Astressin B","moa":"CRF1\/CRF2 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sentia Medical Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sentia Medical Science \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Enzyme Replacement","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"The Bayshore Trust","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Telomir-1","moa":"IL-17 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ The Bayshore Trust","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ The Bayshore Trust"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
ADI-100 is designed to reprogram, downregulate pro-inflammatory cytokines while upregulating anti-inflammatory cytokines in an antigen-specific manner. it is being investigated for Type 1 Diabetes.
Details :
The partnership aims to support the development of cellular therapies by using gene editing of PluriBank cells for Humacyte’s use in developing its investigational BioVascular Pancreas (BVP).
Details :
BMF-219 (icovamenib) is an oral, Menin inhibitor small molecule drug, being investigated in combination of semaglutide for the treatment of Diabetes Mellitus and obesity.
Details :
The funding will support the advancement of a TIX100, oral drug candidate that targets thioredoxin-interacting protein. It is being evaluated for the treatment of type 1 diabetes.
Details :
ADI-100 is designed to reprogram, downregulate pro-inflammatory cytokines while upregulating anti-inflammatory cytokines in an antigen-specific manner. it is being investigated for Type 1 Diabetes.
Details :
The funding will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate developing to treat diabetes.
Reset All
